Evidence map›Paper›PMID 41684894›Full record

ArticleFrontiers in microbiology2025

Camptothecin-PHA nanoparticles attenuate drug-induced gut microbiome dysbiosis and metabolic toxicity.

Shanshuo Liu, Benchen Rao, Wenjie Liu, Xuemei Wang, Haiyu Wang, Liwen Liu, Guizhen Zhang, Junyi Sun, Lei Li, Daixu Wei and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Unveiling the Diagnostic Value and Potential Therapeutic Targets of Phenylalanine Metabolism in Pancreatic Cancer via Integrated Multi-Omics and Machine Learning.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Shanshuo Liu *Department of Infectious Diseases, State Key Laboratory of Antiviral Drugs, Pingyuan Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Benchen Rao *Department of Infectious Diseases, State Key Laboratory of Antiviral Drugs, Pingyuan Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Wenjie Liu *Department of Pain Management, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Xuemei WangDepartment of Infectious Diseases, State Key Laboratory of Antiviral Drugs, Pingyuan Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Haiyu WangDepartment of Infectious Diseases, State Key Laboratory of Antiviral Drugs, Pingyuan Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Liwen LiuDepartment of Infectious Diseases, State Key Laboratory of Antiviral Drugs, Pingyuan Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Guizhen ZhangDepartment of Infectious Diseases, State Key Laboratory of Antiviral Drugs, Pingyuan Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Junyi SunDepartment of Infectious Diseases, State Key Laboratory of Antiviral Drugs, Pingyuan Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Lei LiDepartment of Infectious Diseases, State Key Laboratory of Antiviral Drugs, Pingyuan Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Daixu WeiZigong Institute of Brain Science, Zigong Psychiatric Research Center, Zigong Affiliated Hospital of Southwest Medical University, Zigong, China.
Zujiang YuDepartment of Infectious Diseases, State Key Laboratory of Antiviral Drugs, Pingyuan Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Zhigang RenDepartment of Infectious Diseases, State Key Laboratory of Antiviral Drugs, Pingyuan Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The anticancer drug camptothecin (CPT) has limited clinical applications due to severe toxic reactions. Methods: We combined CPT with PHBVHHx (PHA) nanoparticles by a modified emulsion method for the first time construct a novel nanomedical drug (CPT-PHA-NPs, CPNs). Results: Discussion: In conclusion, this novel type of nanomaterial not only possesses excellent performance but also can reduce the impact of CPT on tissues, intestinal flora and serum metabolism, providing a new strategy for anti-tumor treatment that takes into account both microbial homeostasis and metabolic safety.

Indexed as

camptothecingut microbiomenanoparticlesPHBVHHxserum metabolism

Identifiers

PMID41684894
PMCPMC12893722

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.